antigen proved sensitive (100%) and specific (97.9%). As a quick, simple and costeffective test it has considerable utility in screening for acute HCV.
A c c e p t e d M a n u s c r i p t
Introduction
Outbreaks of acute hepatitis C are being increasingly reported, almost exclusively amongst HIV-positive men-who-have-sex-with-men (MSM). The incidence is at least 8 fold greater than HIV-uninfected MSM [1] , which may be driven by an increase in plasma and semen HCV viral loads in the presence of HIV along with a resurgence of unsafe sexual practices, injecting and other recreational drug use [2] .
Less than half of those acutely infected with HCV experience symptoms and, if present, those symptoms are frequently non-specific [3] . It is therefore recommended in American, European and British guidelines that HIV-positive MSM should be screened for HCV at 6-month intervals with serum transaminases and at least annually with anti-HCV antibody [4, 5, 6] . However, it is well recognized that HCV-antibody seroconversion can be delayed in HIV-infected individuals, with only two-thirds positive at 3 months and 5% remaining negative up to 1 year after infection [7, 8] . This has significant implications for timely diagnosis, treatment, partner notification, contact tracing and reduction of onward transmission.
Furthermore individuals who have cleared previous HCV infection remain HCVantibody positive making it an unhelpful marker for screening for re-infection. As HCV treatment expands with wider availability of all-oral therapy a cost-effective screening test for reinfection will be increasingly important.
As such, a nucleic acid amplification test for HCV-RNA by quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) is recommended in this group if transaminases are elevated or if there has been a high-risk exposure [4, 5, 6] .
A c c e p t e d M a n u s c r i p t technical skills and equipment. A cheaper and quicker assay for initial testing for suspected HCV is needed, particularly in low-resource settings [9] .
Less expensive and time-consuming tests against HCV core-antigen have recently become available, which may be useful in diagnosing acute infection. HCV coreantigen can be used as a marker of viraemia as there is good non-linear correlation with HCV-RNA (r=0.87 vs. Abbot Real-Time qRT-PCR) with the lower limit of detection corresponding to HCV viral load of 700-1100 IU/ml [10] . This assay is available in Europe, Canada, Australasia, South and Central America and Asia but FDA-approval has not yet been sought for the USA. To date only three studies have been published in the co-infected population, including only one using the Abbot Architect platform. For this reason, routine use of HCV core-antigen testing in either mono-or co-infected patients cannot be currently recommended and more data is needed [5, 6] In this study we compare the utility of HCV core-antigen compared to qRT-PCR in the diagnosis on acute HCV in an HIV-positive cohort.
Methods
Subjects were patients attending a dedicated HIV outpatient clinic. Routine liver function tests were performed every 4-6 months in all patients as per British HIV Association monitoring guidelines [11] . Individuals with newly elevated alanine transaminase (ALT) levels above the laboratory upper limit of normal (>41 IU men; 
HCV Antibody testing (Abbott Architect)
Those with chronically elevated and stable ALT for an already established diagnosis (e.g steatohepatitis) were excluded. As per manufacturer's guideline, a cut-off of 10 fmol/L for HCV antigen positivity with an indeterminate zone between 3 -10 fmol/L was adopted. Retrospective testing of stored samples determined acute versus chronic HCV infections, the latter being excluded from the study, consistent with the European recommendations for diagnosing acute infection [5] .
Statistical analysis using SPSS was performed; multivariate analysis, sensitivity, specificity, positive and negative predictive value calculations were calculated, and Spearman coefficient calculated for the correlation between qRT-PCR and HCV Ag. whether it was extremely early infection that failed to amplify on qRT-PCR as we had no interim samples which could be analysed. As we are using qRT-PCR as the goldstandard in this analysis we have included that result as a false-indeterminate.
Specificity of HCV core antigen is therefore 97.96% (95% CI = 92.1% -99.6%) with a positive predictive value of 88% (95% CI = 62.2% -97.9%) and a negative predictive value of 100% (95% CI = 95.2% -100%). Similar sensitivity (100%) and specificity (97.7%) has been reported in abstract form by another study using the same platform comparing stored serum panels from HIVpositive patients with known acute HCV, chronic HCV, or negative for HCV [12] . Inkeeping with existing data in HIV-negative people HCV core-antigen sensitivity dropped off at low HCV viral loads (625 IU/ml) [10] . Such low viral loads are rarely seen in HIV/HCV co-infection. Furthermore, in our study 3 re-infections occurred within the time period, an increasingly recognized phenomenon, supporting the utility of antigen testing in detecting acute re-infection. In HIV-negative cohorts other studies also report sensitivities in excess of 90% with the Architect platform [10] . HCV core-antigen's utility in low-resource settings, where PCR may be unavailable, would be even more significant [9] . Compared with HCV antibody screening alone this test considerably shortens the diagnostic window, as the delay to antibody seroconversion previously reported by others after PCR positivity is confirmed here after antigen positivity [7] .
The main limitation of our study is the small sample size. Other general test limitations include potential low-level false positive from antigen carry-over from the A c c e p t e d M a n u s c r i p t
